2019 Volume 36 Issue 3 Pages 117-122
It is thought to be the most important theme for neurogenic disease is the neurotherapeutics not only now but also in the future.
Our department of neurology of Dokkyo Medical University have done mainly clinical research for developing the neurotherapeutic in many field. We found many new results and published using neurophysiological and neuro–immunological technic and field work in sleep disorders, a migraine headache, cerebrovascular disease, cognitive impairment and neurologic immune disorders. We have done also many promotion to prevent stroke and other disease.
However, there are still some intractable neurological disorders with unknown causes that have a progressive clinical course still now. In addition, we are facing on the super low birthrate and aged society in the present. Moreover, it will be continued and spread till around 2040. Therefore, looking for the future it must be important to develop new treatments for such neurological disorders.
First of all, new drug for the neurological disorder should be approved more effectively using so called delayed–start study design.
Furthermore, gene therapy, innovative drug development such as disease modifying drug using iPS cell, genome information and big data analysis will be important. In addition, progress of nerve stimulation and new rehabilitation technic will be necessary. Promotion of brain machine interface (BMI) and the regenerative therapy for function reproduction is required. Probably contribution of the AI will be important.
On the other hand, JSNT have to be focusing on preventive health care with a medical practitioner, nurses and other medical stuffs.
Education for young doctors, nurses and medical staff sabout the treatment of neurological disorders are also important. JSNT is preparing some educational programs every year and publishing guidelines for the treatment of neurological disorders.
As activity that we pay more attention to the world, JSNT is involved in exchanges with the American Society for Experimental Neuro Therapeutics (ASENT). The mission of ASENT is to facilitate cooperation between academia, government, industry, the clinical community and advocacy groups to enable and advance the discovery, translation, and development of neurotherapeutics. An ongoing partnership between ASENT and JSNT are successful and productive.
Thus, JSNT is contributing to progress in the treatment of neurological disorders and a role and the importance of JSNT will increase more in future.
